Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call 602-406-7437 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
Valley nurse fighting brain cancer sees promising results from treatment
Tim Jackson, a valley nurse, was diagnosed with brain cancer in February 2021. Tim and his wife, Amber, joined ABC15 to discuss their journey with glioblastoma and their exploration of clinical trials at the Ivy Brain Tumor Center. Read his full story here.
The Game On Glio Podcast: Episode 10 with Guest Dr. Sanai
Dr. Nader Sanai, director of Ivy Brain Tumor Center, joined Shannon Traphagen, Host of the “Game on Glio” podcast, to share his career in neurosurgical oncology. Dr. Sanai discusses the work happening at the Ivy Brain Tumor Center and the progress being made toward discovering a cure for brain cancer.
Ivy Brain Tumor Center’s core labs earn accreditation
The Ivy Brain Tumor Center is pleased to announce that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP). Learn more ->
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).
Diamondbacks GM Mike Hazen and wife give back to support cancer research
The Hazen's presented a $1.5 million check to doctors, physicians and researchers at the Ivy Brain Tumor Center at the Barrow Neurological Institute. Nicole is receiving treatment and care at the Ivy Center after she was diagnosed in July 2020 with glioblastoma, a rare form of brain cancer.
StacheStrong Raises $340,000 for the Ivy Brain Tumor Center’s Innovative Phase 0 Clinical Trial of Sonodynamic Therapy for Patients with Glioblastoma
StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, announced they raised $340,000 for the Ivy Brain Tumor Center at Barrow Neurological Institute.
GlaxoSmithKline Starts Brain Cancer Trials With Key Drug Zejula
GlaxoSmithKline Plc is partnering with the Ivy Brain Tumor Center to test one of its key oncology medicines against brain cancer as the British pharmaceutical giant looks to expand the drug’s use.
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer
The Ivy Center in collaboration with UCSF Department of Neurological Surgery is pleased to announce a new clinical trial of GSK’s niraparib (ZEJULA) – an FDA-approved drug to treat ovarian cancer – for patients with newly diagnosed glioblastoma and recurrent high-grade gliomas.
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
The Ivy Brain Tumor Center's clinical trial of sonodynamic therapy provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors
Ivy Brain Tumor Center Announces Results from Phase 0/1 Clinical Trial of Ribociclib Plus Everolimus in Recurrent High-Grade Glioma
Published in the journal of Neuro-Oncology and presented at the European Association of Neuro-Oncology, the Ivy Brain Tumor Center announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).